Unknown PHASE2 INTERVENTIONAL NCT00807261

Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy

PhaseⅡ Study of Weekly Docetaxel and Fixed-Dose Rate Gemcitabine in Patient With Previously Treated Advanced Soft Tissue and Bone Sarcoma Prospective, Open Label, Multi-Institutional

Sponsor: Asan Medical Center

Conditions Sarcoma

Interventions Gemcitabine and Docetaxel

Updated 6 times since 2017 Last updated: Dec 11, 2008 Started: Sep 30, 2008 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Sarcoma and is currently ongoing. Asan Medical Center leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Enrolling By Invitation → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Enrolling By Invitation PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asan Medical Center
Korea University Anam Hospital
Samsung Medical Center
Severance Hospital

Data source: Asan Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.